Live Procedure in Germany Highlights Benefits and Ease-of-Use of MUSE ™ to Top Endoscopists in Europe; Renowned gastroenterologists, Professors Messmann and Neuhaus, demonstrate transoral fundoplication with Medigus ’ MUSE at Endo-Update in Augsberg, Germany

OMER, Israel, Dec. 13, 2016 -- Medigus Ltd. (Nasdaq:MDGS) (TASE:MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced the completion of a live transoral fundoplication (TF) procedure using the Medigus Ultrasonic Surgical Endostapler (MUSE™) system. The procedure was performed at the Endo-Update, one of the largest and most well-attended live endoscopy conferences in Europe, by renowned gastroenterologists from Germany, Professors Helmut Messmann, Klinikdirektor and Internist, Gastroenterologe at Klinikum Augsberg and Horst Neuhaus, MD, Head of the Department of Gastroenterology of the Evangelisches Krankenhaus in Düsseldorf, Germany.
Published: 13 December 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Medigus Ltd ( MDGS )

Neovasc Provides Update on its Tiara™ Mitral Valve Clinical Program

-Recent results presented at the ICI Meeting in Israel-
 
VANCOUVER, Dec. 6, 2016 - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today provided an update on the clinical experience with its Tiara™ transcatheter mitral valve.  Tiara™ is a novel transcatheter device designed to treat mitral regurgitation (MR), a condition that is often severe and can lead to heart failure and death.
 
To date, 22 patients have been treated with the Tiara™ valve at medical centers in Canada, the U.S. and Europe with more implantations scheduled for the coming weeks.  The technical success rate in these implantations was 19/22 or 86%.  In these technically successful implantations, paravalvular leak levels were reported as mild, trace or absent in 100% of these cases.  All cause 30-day mortality in the 19 patients who have reached 30 days post implant with Tiara™ is 15.7% (3/19).  The 3 remaining patients treated within the last 30 days are recovering well.  Of note, there has been no 30-day mortality reported in any of the last 8 patients treated over a month ago.  
Published: 06 December 2016
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Neovasc Inc ( NVC / NVCN )

TSO3 Receives 2017 Purchase Orders from Getinge

Backlog for the STERIZONE® VP4 Sterilizer Exceeds $18 Million
 
QUÉBEC CITY, Dec. 2, 2016 / - TSO3 Inc. (TSX:TOS.TO - News) ("TSO3" or the "Company"), an innovator in sterilization technology for medical devices in healthcare settings, has received initial purchase orders from Getinge USA, Inc., for fiscal 2017. These orders will increase the rate of production and throughput from the Company's assembly facility in Quebec throughout 2017.
 
The purchase orders were received in association with the distribution agreement signed with Getinge in November 2015.
"This PO from Getinge provides a degree of operational predictability for 2017 as it enables TSO3 to leverage supply chain improvements achieved in fiscal 2016," said R.M. (Ric) Rumble, TSO3's President and CEO. "We look forward to further collaboration and success as we enter our second year of this strategic partnership. TSO3, together with Getinge continue to collaborate and deploy an increasing number of sterilizers and deliver on our vision – Creating the Improved Standard in Healthcare Sterile Reprocessing™."
Published: 02 December 2016
Written by Editor
TSX   New Product or Order   Up on News  
Read more: TSO3 Inc ( TOS )

Neovasc and Boston Scientific Reach US$75 Million Agreement

- Boston Scientific acquires tissue processing capabilities and takes equity stake in Neovasc -
 
VANCOUVER, Dec. 2, 2016 - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVC.TO - News) today announced that Boston Scientific Corporation (NYSE:BSX - News), a global medical technology leader, has agreed to acquire Neovasc's tissue processing technology and facility for approximately US$67,909,800. Concurrently, Boston Scientific has committed to invest an additional US$7,090,200 in Neovasc for a 15% equity interest in the Company.
 
"Boston Scientific has been a long-term customer of Neovasc, having historically represented a sizeable percentage of our tissue processing revenues," commented Neovasc CEO, Alexei Marko. "As one of the world's premier device companies, with a global cardio-vascular franchise, this investment in Neovasc enables continued development of our lead products, Reducer and Tiara, and strengthens our resolve to revolutionize how structural heart disease is treated."
Under the terms of the equity investment, Boston Scientific has agreed to purchase 11,817,000 common shares in the capital of Neovasc (the "Common Shares") at a price of US$0.60 per Common Share, for gross proceeds of US$7,090,200, subject to required regulatory approvals, including approval of the Toronto Stock Exchange.
Published: 02 December 2016
Written by Editor
Nasdaq   Up on News  
Read more: Neovasc Inc ( NVC / NVCN )

Medigus Expands Global Commercial Availability of MUSE™ Through Distribution Agreement With INNOVAMEDICA S.p.A. In Italy; New agreement broadens Medigus’ accessibility in key markets around the world

OMER, Israel, Nov. 22, 2016  -- Medigus Ltd. (MDGS) (MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced a distribution agreement in Italy with INNOVAMEDICA S.p.A, a privately owned distributor of minimally invasive medical devices. Under terms of the four-year agreement which will take effect January 1st 2017, INNOVAMEDICA S.p.A. will be required to purchase at least 1M € of Medigus Ultrasonic Surgical Endostapler (MUSE™) equipment over the course of the agreement.
Published: 23 November 2016
Written by Editor
Nasdaq   Up on News  
Read more: Medigus Ltd ( MDGS )
  1. Skyline Medical Inc ( SKLN )
  2. Intersect ENT Inc ( XENT )
  3. AtriCure Inc ( ATRC )
  4. Second Sight Medical Products ( EYES )
  5. PhotoMedex Inc ( PHMD )